Tag:
John Johnson
Latest Headlines
Latest Headlines
Savient hammered after hedge fund claims it's bankrupt
John Johnson has a good reason today to be thankful for his new job at Dendreon: He won't have to face the music at Savient.
What will Dendreon's new chief do about Provenge?
It's safe to say Dendreon ( $DNDN ) is looking for a new Provenge strategy when board member John Johnson takes over as CEO. The $93,000 prostate-cancer drug, approved to great fanfare in spring 2010,
Savient names ImClone's Johnson as new CEO
Ex-ImClone president John H. Johnson is back in the biotech saddle. Savient Pharmaceuticals named Johnson, who ran Eli Lilly's oncology business after the pharma company snatched up ImClone, as its
ImClone: Stock buy timing a coincidence
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson
More great investment timing by an ImClone CEO
Talk about great timing: new ImClone CEO John Johnson (formerly, yes, of Johnson & Johnson) did his
